Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

Epiminder plans to launch its GO Minder system in the US during the first half of 2026 using funds from the IPO, which raised ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Speaking to the media, Shuchit Pandey, neurophysician at Ahmedabad Civil Hospital, underscored the importance of dispelling misconceptions surrounding epilepsy. He noted that seizures, commonly ...

Having raised $125 million, the Cochlear-based Epiminder lists next Monday on the back of its groundbreaking epilepsy ...

Every November, Epilepsy Awareness Month highlights one of the world’s most misunderstood neurological disorders: the stigma, ...

This review contrasts the standard of care for focal epilepsy with the complex reality of managing non-lesional and ...

Epilepsy is still surrounded by harmful myths and stigma. This expert-backed guide breaks down the most common misconceptions ...

Epiminder shares have made a lacklustre start to life on the ASX, despite positive market developments in the US.

Sudden unexpected death in epilepsy (SUDEP) is a leading cause of premature death, affecting 1·00–1·14 per 1000 people with epilepsy annually.1 Identifying those at high risk or low risk of SUDEP is ...

Melbourne-based Epiminder plans to use the funds from its initial public offering to commercialise a device it says could ...

CeriBell supported its latest FDA clearance with EEG data from more than 700 patients. It says that represented the largest ...